AbbVie Defends Humira With Aggressive Discount In First EU Tender

AbbVie has reportedly slashed the price of its TNF inhibitor Humira by 80% in the first European tender for biosimilar adalimumab, far beyond the 50% discount previously thought.

Brown bear
AbbVie has laid down its defense of Humira's European market • Source: Shutterstock

AbbVie Inc. is ready for a fight to keep rivals away from having their piece of the biosimilar adalimumab market if reports of a price cut of 80% are anything to go by.

The discount in an, as yet, unknown market, is not expected to hurt AbbVie much financially. Even with the 80%...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Strategy

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.